Literature DB >> 16760181

Expression of bcl-2 family members in malignant pleural mesothelioma.

Sara L O'Kane1, Rachelle J Pound, Anne Campbell, Nilanjan Chaudhuri, Michael J Lind, Lynn Cawkwell.   

Abstract

Little is known about the Bcl-2 family members in mesothelioma. These proteins are involved in the control of apoptosis, carrying out both pro- and anti- apoptotic functions. Immunohistochemistry was used to examine the expression of p53 and Bcl-2 family members in 54 archival mesothelioma samples (39 epithelial, 15 sarcomatoid tumours). Overexpression of p53 was observed in 81% (44/54). For anti-apoptotic proteins, overexpression was recorded as follows: Bcl-2 40% (22/54), Bcl-XL 24% (13/54), Mcl-1 92% (50/54). For pro-apoptotic proteins, loss of expression was recorded as follows: Bad 25% (14/54), Bak 24% (13/54), Bax 42% (23/54), Bid 37% (20/54), Bim 18% (10/54). Statistically significant differences between epithelial and sarcomatoid tumours were observed for Bid (p < 0.001), Bad (p = 0.012) and Bcl-XL (p = 0.03). Significant differences in abnormal expression of apoptosis proteins were found between epithelial and sarcomatoid subtypes but histological subtype was the only factor with significant association to patient prognosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16760181     DOI: 10.1080/02841860500468927

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  14 in total

1.  MicroRNA-302b targets Mcl-1 and inhibits cell proliferation and induces apoptosis in malignant pleural mesothelioma cells.

Authors:  Nazli Khodayari; Kamal A Mohammed; Hungyen Lee; Frederick Kaye; Najmunnisa Nasreen
Journal:  Am J Cancer Res       Date:  2016-09-01       Impact factor: 6.166

2.  hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma.

Authors:  Harvey I Pass; Chandra Goparaju; Sergey Ivanov; Jessica Donington; Michele Carbone; Moshe Hoshen; Dalia Cohen; Ayelet Chajut; Shai Rosenwald; Harel Dan; Sima Benjamin; Ranit Aharonov
Journal:  Cancer Res       Date:  2010-02-16       Impact factor: 12.701

Review 3.  Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunities.

Authors:  Jessica Plati; Octavian Bucur; Roya Khosravi-Far
Journal:  J Cell Biochem       Date:  2008-07-01       Impact factor: 4.429

Review 4.  Biomarkers for malignant pleural mesothelioma: current status.

Authors:  Laurent Greillier; Paul Baas; John J Welch; Baktiar Hasan; Alexandre Passioukov
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

5.  Does the expression of BCL2 have prognostic significance in malignant peritoneal mesothelioma?

Authors:  Krishna Pillai; Mohammad H Pourgholami; Terence C Chua; David L Morris
Journal:  Am J Cancer Res       Date:  2013-06-20       Impact factor: 6.166

6.  Expression of Bim, Noxa, and Puma in non-small cell lung cancer.

Authors:  Jun Sakakibara-Konishi; Satoshi Oizumi; Junko Kikuchi; Eiki Kikuchi; Hidenori Mizugaki; Ichiro Kinoshita; Hirotoshi Dosaka-Akita; Masaharu Nishimura
Journal:  BMC Cancer       Date:  2012-07-12       Impact factor: 4.430

7.  Blocking of ERK1 and ERK2 sensitizes human mesothelioma cells to doxorubicin.

Authors:  Arti Shukla; Jedd M Hillegass; Maximilian B MacPherson; Stacie L Beuschel; Pamela M Vacek; Harvey I Pass; Michele Carbone; Joseph R Testa; Brooke T Mossman
Journal:  Mol Cancer       Date:  2010-12-15       Impact factor: 27.401

8.  Expression of cancer-associated molecules in malignant mesothelioma.

Authors:  Ben Davidson
Journal:  Biomark Insights       Date:  2007-05-30

9.  BAK and NOXA are critical determinants of mitochondrial apoptosis induced by bortezomib in mesothelioma.

Authors:  Sara Busacca; Alex D Chacko; Astero Klabatsa; Kenneth Arthur; Michael Sheaff; Dario Barbone; Luciano Mutti; Vignesh K Gunasekharan; Julia J Gorski; Mohamed El-Tanani; V Courtney Broaddus; Giovanni Gaudino; Dean A Fennell
Journal:  PLoS One       Date:  2013-06-07       Impact factor: 3.240

10.  Somatic Epigenetic Silencing of RIPK3 Inactivates Necroptosis and Contributes to Chemoresistance in Malignant Mesothelioma.

Authors:  Yinfei Tan; Eleonora Sementino; Mitchell Cheung; Suraj Peri; Craig W Menges; Anna-Mariya Kukuyan; Ting Zhang; Vladimir Khazak; Lauren A Fox; Eric A Ross; Suresh Ramanathan; Suresh C Jhanwar; Raja M Flores; Siddharth Balachandran; Joseph R Testa
Journal:  Clin Cancer Res       Date:  2020-11-17       Impact factor: 13.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.